ArticlePloS one2022

Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.

Jayoung Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.